Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
our-team
practice-areas
investment-products

Investigations

Onglyza and Kombiglyze XR Lawsuits Filed After Adverse Cardiac Events

[et_pb_section bb_built=”1″ background_color=”#ffffff” custom_padding=”230px||0px|” _builder_version=”3.0.67″ background_image=”https://lawgsp.com/wp-content/uploads/2017/02/defective_banner1.jpg”][et_pb_row make_fullwidth=”on” use_custom_gutter=”on” gutter_width=”1″ custom_padding=”||0px|” custom_margin=”||0px|” background_color=”rgba(46,78,103,0.7)” padding_top_1=”0px” padding_bottom_1=”10px” padding_left_1=”5%” background_position_1=”top_left” background_repeat_1=”no-repeat” _builder_version=”3.0.71″][et_pb_column type=”4_4″][et_pb_text admin_label=”hero header” background_layout=”dark” _builder_version=”3.0.67″]

Onglyza Lawsuit

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#f4f4f4″ custom_padding=”0px|0px|0px|0px” padding_mobile=”on” _builder_version=”3.0.55″][et_pb_row admin_label=”row” make_fullwidth=”on” use_custom_gutter=”on” gutter_width=”1″ custom_padding=”0px||0px|” custom_margin=”0px||0px|” make_equal=”on” background_color=”#ffffff” background_color_2=”#f4f4f4″ padding_top_1=”50px” padding_right_1=”7%” padding_bottom_1=”50px” padding_left_1=”7%” padding_top_2=”50px” padding_right_2=”3%” padding_bottom_2=”0px” padding_left_2=”3%” parallax_method_1=”off” parallax_method_2=”off” background_position_1=”top_left” background_position_2=”top_left” background_repeat_1=”no-repeat” background_repeat_2=”no-repeat” padding_1_tablet=”30px|5%|20px|5%” padding_2_tablet=”30px|3%|0px|3%” padding_1_phone=”20px|5%|20px|5%” padding_2_phone=”20px|3%|0px|3%” padding_1_last_edited=”on|desktop” padding_2_last_edited=”on|desktop” custom_padding_last_edited=”on|phone” _builder_version=”3.0.55″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin_last_edited=”on|desktop”][et_pb_column type=”2_3″][et_pb_text _builder_version=”3.0.67″ header_font_size_tablet=”24px” header_font_size_phone=”18px” header_font_size_last_edited=”on|phone” background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

Onglyza and Kombiglyze XR Lawsuits Filed After Adverse Cardiac Events

Pharmaceutical giants AstraZeneca and Bristol-Meyers Squibb are facing lawsuits filed by patients who experienced heart problems after taking prescription drugs Onglyza and Kombiglyze XR to help manage their type 2 diabetes. The active ingredient in both Onglyza and Kombiglyze XR is saxagliptin, a DPP-4 inhibitor that helps lower blood glucose levels. Studies have shown that patients taking Onglyza and Kombiglyze XR face an increased risk of hospitalization for heart failure.

The first case against AstraZenica relating to Onglyza lawsuit was filed in October 2015 by a Chicago woman who alleged that Onglyza led to her mother’s death. It was filed in Cook County Circuit Court on behalf of the estate of Lillie Ree Gibson and alleges that Ms. Gibson began taking Onglyza in 2010 upon doctor’s orders, which led to her heart problems and subsequent death on Oct. 31, 2013. The suit says she was diagnosed with heart failure in June 2011, and was hospitalized twice in 2013 for her heart condition before she passed away. Ms. Gibson’s family filed the lawsuit seeking damages and attorney’s fees.

In February 2017, Texas resident Wrendell Chester filed a heart failure lawsuit against AstraZeneca and Bristol-Meyers Squibb. According to the lawsuit, Chester developed severe complications after ingesting saxagliptin from 2010 to 2015, including heart failure, congestive heart failure, and acute hypoxic respiratory failure. According to the lawsuit, AstraZeneca and Bristol-Meyers Squibb failed to warn Mr. Chester, other patients, consumers and medical providers about any potentially life-threatening side effects before they took or prescribed the drug. The lawsuit says AstraZeneca’s marketing over-promoted Onglyza and Kombiglyze XR and downplayed the drugs’ risks.

In May 2017, fourteen New Jersey plaintiffs with near-identical Onglyza and Kombiglyze XR lawsuits consolidated their litigation efforts against AstraZeneca and Bristol-Meyers Squibb. Some of the New Jersey cases were originally filed in San Francisco, but re-filed in New Jersey after the San Francisco judge granted a motion to sever and dismiss non-California plaintiffs from the case. It is believed there are approximately 150 lawsuits pending across the country seeking damages against AstraZeneca and Bristol-Meyers Squibb for the potentially life-threating harm suffered by patients who took Onglyza or Kombiglyze XR.

Bristol-Meyers Squibb received Food and Drug Administration approval for Onglyza in July 2009 without undergoing any premarket cardiovascular risk tests, despite a strong recommendation by the FDA in 2008 that new diabetic therapies undergo such a risk assessment before approval. The FDA approved Kombiglyze XR in 2010. In 2014, AstraZeneca acquired Bristol-Meyers Squibb’s diabetes drug portfolio.

On February 11, 2014, the FDA issued a Safety Communication announcing it was investigating a possible increased risk for heart failure for patients taking Onglyza and Kombiglyze XR following a study published in the New England Journal of Medecine reporting on a clinical study that found an increased rate of hospitalization for heart failure in patients taking saxagliptin over patients in a control group.

On April 5, 2016, the FDA issued a Safety Announcement that drugs containing saxagliptin (Onglyza and Kombiglyze XR), may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. Onglyza’s label was revised in February 2017 to add the risk of heart failure as a Warning and Precaution.

Protect Your Rights

If you or a loved one have suffered heart failure, congestive heart failure, cardiac complications or death while taking ONGLYZA or KOMBIGLYZE XR to treat type 2 diabetes you may be entitled to compensation. Please contact us today.

There are time limits by which you need to file a product liability lawsuit. Those limits could time bar your case if it is not filed in a timely manner. Your state of residence, when you ingested the drug and when you experienced injuries could all affect how much time you have to file.

Contact Us

Complete the form and one of our attorneys will reach out to you within 24 hours to conduct a free and confidential evaluation of your case.

[/et_pb_text][/et_pb_column][et_pb_column type=”1_3″][et_pb_text module_id=”contact” _builder_version=”3.0.71″ header_font=”Lato|on|||” header_font_size=”24px” background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding_last_edited=”on|tablet” background_layout=”light” text_orientation=”left” border_style=”solid”]

FREE CASE REVIEW


If you believe you or a loved one may have an Onglyza claim, contact us today. One of our attorneys will contact you within 24 hours to conduct a free and confidential evaluation of your case.

[gravityform id=”10″ title=”false” description=”false”]

[/et_pb_text][et_pb_sidebar orientation=”right” area=”et_pb_widget_area_3″ remove_border=”on” _builder_version=”3.0.67″ /][/et_pb_column][/et_pb_row][/et_pb_section]

In our legal system, every person is innocent until and unless found guilty by a court of law or a tribunal. Whenever we reference “allegations” or charges that are “alleged,” such allegations or charges have not been proven, and are merely accusations, not findings of fault, as of the date of the blog. We do not have, nor do we undertake, a duty to continue to monitor or follow cases about which we report, and/or to publish subsequent updates regarding various developments that may occur in such cases. Readers are encouraged to conduct their own research regarding any such cases and any developments that may or may not have occurred in such cases. Also, the brokercheck report linked to some of our blogs is the up-to-date version as of the date of posting. Visitors may check the most recent version of each brokercheck report at www.finra.org.

Leave a Reply